Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
FTRE is expected to report earnings to rise 173.91% to 62 cents per share on November 05
Q3'26
Est.
$0.63
Q2'26
Missed
by $0.36
Q1'26
Beat
by $0.11
Q4'25
Missed
by $0.44
Q3'25
Missed
by $0.36
The last earnings report on July 29 showed earnings per share of 23 cents, missing the estimate of 58 cents. With 327.50K shares outstanding, the current market capitalization sits at 1.72B.